GO:0000151 ubiquitin ligase complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0000151 (ubiquitin ligase complex) is a cellular component defined as a protein complex that includes a ubiquitin-protein ligase and enables ubiquitin protein ligase activity, often with additional subunits that confer substrate specificity.
• The complex catalyzes the final step of ubiquitin conjugation, transferring ubiquitin from an E2 conjugating enzyme to a substrate lysine, thereby controlling protein stability, localization, and interactions.
• Major families include RING-type and HECT-type ligases; multi-subunit CRL complexes (e.g., CUL3-based) illustrate how substrate adaptors and accessory proteins assemble into functional ligases.
• Dysregulation of ubiquitin ligase complexes is implicated in cancer, cardiac remodeling, and protein quality control disorders, making them attractive therapeutic targets.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of ligase complex subunits and their substrates.
• EDITGENE provides end-to-end CRISPR cell model generation and library screening to study ubiquitin ligase complex biology at scale.
Description
The ubiquitin ligase complex (GO:0000151) is a cellular component that brings together a ubiquitin-protein ligase with additional proteins to enable ubiquitin transfer to specific substrates. This complex is the execution point of the ubiquitin system, determining which proteins are modified, when, and with what ubiquitin chain topology. Because ubiquitination governs protein degradation, trafficking, and signaling, the composition and regulation of ubiquitin ligase complexes are central to nearly every cellular process. Researchers study GO:0000151 to understand substrate selection, catalytic mechanisms, and how complex assembly is controlled. The term is also clinically relevant: mutations or expression changes in ligase complex subunits are linked to cancer, cardiovascular disease, and neurodegeneration. As a result, ubiquitin ligase complexes are actively pursued as drug targets, and CRISPR-based models are essential for validating subunit function and substrate relationships.
ubiquitin ligase complex At A Glance
| GO ID | GO:0000151 |
|---|---|
| GO term | ubiquitin ligase complex |
| Ontology | cellular_component |
| Synonym | none |
| Definition | A protein complex that includes a ubiquitin-protein ligase and enables ubiquitin protein ligase activity; the complex also contains other proteins that may confer substrate specificity. |
| Major function | Catalyzes ubiquitin transfer to substrate proteins, often determining substrate specificity and chain topology. |
| Example complexes | Cullin-RING ligases (CRLs) such as CUL3-based complexes, and HECT-type ligase assemblies. |
| Associated processes | Protein degradation, signal transduction, DNA repair, cell cycle control, and quality control. |
| Disease relevance | Cancer, cardiac remodeling, and protein quality control disorders. |
What Is GO:0000151?
According to the Gene Ontology, GO:0000151 (ubiquitin ligase complex) is a protein complex that includes a ubiquitin-protein ligase and enables ubiquitin protein ligase activity. The complex also contains other proteins that may confer substrate specificity on the complex. In other words, it is not a single enzyme but an assembly of proteins whose combined function is to attach ubiquitin to target proteins, often with dedicated subunits that recognize substrates and regulate activity.
Why Is ubiquitin ligase complex Important in Cell Biology?
Ubiquitin ligase complexes are the substrate-specific engines of the ubiquitin system, and their activity determines the fate of thousands of proteins. Because they control protein stability and function, they are essential for normal development and homeostasis, and their dysregulation contributes to major human diseases including cancer and heart disease. Understanding GO:0000151 therefore provides mechanistic insight into disease and identifies targets for therapeutic intervention.
• Controls selective protein degradation and turnover, influencing nearly all cellular pathways.
• Determines substrate specificity through adaptor and accessory subunits.
• Regulates signaling pathways by modifying key signaling proteins.
• Implicated in cancer through degradation of oncogenes or tumor suppressors.
• Linked to cardiac remodeling via targeted degradation of nuclear proteins.
• Participates in protein quality control and stress responses.
• Provides a large family of druggable targets for therapeutic development.
• Serves as a paradigm for studying multi-subunit complex assembly and regulation.
What Happens During ubiquitin ligase complex?
Substrate recognition and adaptor assembly
In simple terms: The complex first grabs the right target protein.
Ubiquitin ligase complexes often use dedicated substrate adaptors or substrate receptor subunits to recognize specific target proteins. For example, in CRL3 complexes, the BTB-domain protein Keap1 acts as a substrate adaptor for the CUL3-RING ligase, recruiting oncogenic SRX for ubiquitination. Structural studies of KCTD5/CUL3 complexes show how pentameric adaptors can assemble with CUL3 to form an active E3 ligase. This step ensures that only appropriate substrates are modified, providing specificity.
Ubiquitin transfer and chain formation
In simple terms: The complex attaches ubiquitin to the target protein.
Once the substrate is bound, the RING or HECT domain of the ligase catalyzes the transfer of ubiquitin from a thioester-linked E2 conjugating enzyme to a lysine residue on the substrate. This reaction can be processive, leading to polyubiquitin chains that determine the substrate's fate. Different chain linkages (e.g., K48-linked vs. K63-linked) are associated with distinct outcomes such as proteasomal degradation or signaling.
Regulation by complex dynamics
In simple terms: The complex can be switched on or off by changing its parts.
The activity of ubiquitin ligase complexes is regulated by assembly and disassembly of subunits, post-translational modifications, and interaction with regulatory proteins. For instance, the pentameric KCTD5/CUL3 complex exhibits dynamic conformational changes that influence catalytic activity. Deubiquitinases can also counteract ligase activity by removing ubiquitin chains, adding another layer of regulation.
Substrate fate and downstream effects
In simple terms: After tagging, the target protein is sent to a new fate.
The ubiquitin chains added by the ligase complex are recognized by downstream effectors, most commonly the proteasome for degradation, but also by proteins involved in trafficking, DNA repair, or signaling. For example, WWP2-mediated ubiquitination of PARP1 leads to its degradation and regulates cardiac remodeling. In quality control pathways, ubiquitin chain elongation by a ligase complex targets misfolded proteins for clearance.
Key Genes Involved in GO:0000151 ubiquitin ligase complex
The following genes encode core and accessory components of ubiquitin ligase complexes, including E3 ligases, adaptors, and regulatory subunits.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CUL3 | Scaffold for CRL3 complexes | Forms multi-subunit E3 ligases with BTB adaptors; implicated in cancer and cardiovascular disease. |
| KEAP1 | Substrate adaptor for CUL3 | Recruits substrates like SRX for ubiquitination; involved in colorectal cancer suppression. |
| KCTD5 | Adaptor/substrate receptor | Forms pentameric complexes with CUL3; structural model for CRL assembly. |
| WWP2 | HECT-type E3 ligase | Targets PARP1 for degradation; regulates cardiac remodeling. |
| NEDD4 | HECT-type E3 ligase | Broad roles in signaling and protein quality control. |
| MDM2 | RING-type E3 ligase | Targets p53 for degradation; key in cancer. |
| SKP2 | F-box protein in SCF complex | Controls cell cycle regulators; implicated in cancer. |
| FBXW7 | F-box protein in SCF complex | Degrades oncoproteins; frequently mutated in cancer. |
| VHL | Substrate receptor in CRL2 | Targets HIF for degradation; tumor suppressor. |
| RBX1 | RING-box protein | Core catalytic subunit of CRLs. |
| UBE2D1 | E2 conjugating enzyme | Partners with RING ligases for ubiquitin transfer. |
| UBE2L3 | E2 conjugating enzyme | Works with various E3s; linked to immune regulation. |
| DDB1 | Adaptor in CRL4 | Facilitates substrate recognition in CRL4 complexes. |
| DDB2 | Substrate receptor in CRL4 | Recognizes DNA damage; involved in nucleotide excision repair. |
| SOCS1 | Adaptor in CRL5 | Regulates cytokine signaling; targets JAK for degradation. |
| ELOB | Elongin B, adaptor in CRL5 | Forms part of the Elongin BC complex with CUL5. |
| ELOC | Elongin C, adaptor in CRL5 | Partners with SOCS proteins for substrate recruitment. |
| NEDD8 | Ubiquitin-like modifier | Modifies cullins to activate CRLs. |
How Is ubiquitin ligase complex Regulated?
Ubiquitin ligase complex activity is regulated at multiple levels. Cullin-RING ligases are activated by neddylation, a process in which the ubiquitin-like protein NEDD8 is conjugated to the cullin scaffold. Deubiquitinases can remove ubiquitin chains from substrates or from the ligase itself, providing reversible control. Additionally, the assembly and stability of adaptor subunits can be regulated by phosphorylation or other post-translational modifications, as seen in the dynamic behavior of KCTD5/CUL3 complexes. These regulatory mechanisms ensure that ubiquitination is spatially and temporally controlled.
ubiquitin ligase complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KEAP1/CUL3 | Colorectal cancer progression | Knockout of KEAP1 in colorectal cancer cell lines to assess SRX degradation. |
| WWP2 | Cardiac remodeling | Cardiomyocyte-specific knockout or overexpression in mouse models. |
| MDM2 | Cancer (p53 inactivation) | Point mutation of MDM2 RING domain to disrupt ligase activity. |
| FBXW7 | Cancer (oncoprotein degradation) | Knock-in of patient-derived mutations in cancer cell lines. |
| KCTD5/CUL3 | Complex assembly and signaling | Knockout of KCTD5 to study CRL3 complex formation. |
Cancer
Ubiquitin ligase complexes are frequently dysregulated in cancer, where they can either degrade tumor suppressors or oncoproteins. For example, the CRL3(Keap1) complex targets oncogenic SRX for degradation, and its dysfunction can promote colorectal cancer progression. Other ligases such as MDM2 control p53 stability, and their overexpression leads to p53 inactivation. Targeting these complexes with small molecules or degraders is an active therapeutic strategy.
Cardiovascular disease
The E3 ligase WWP2 selectively ubiquitinates and degrades PARP1, and this process regulates cardiac remodeling in response to isoproterenol. This highlights how ubiquitin ligase complexes can influence heart disease and may offer targets for intervention.
Protein quality control disorders
Ubiquitin ligase complexes are central to protein quality control pathways that clear misfolded or damaged proteins. Convergence of orphan quality control pathways at a ubiquitin chain-elongating ligase suggests that defects in these complexes could contribute to diseases characterized by protein aggregation.
From ubiquitin ligase complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a ligase subunit affect substrate stability? | CRISPR knockout cell line (e.g., CUL3 KO). |
| Does a specific point mutation abolish catalytic activity? | Point mutation knock-in (e.g., RING domain mutant). |
| How does a disease-associated mutation affect complex assembly? | Knock-in of patient mutation in endogenous locus. |
| Where and when is the ligase expressed? | Tagged knock-in (e.g., GFP or HA tag) for imaging and immunoprecipitation. |
| What happens when the ligase is overexpressed? | Overexpression cell line via lentiviral transduction. |
| Which substrates are targeted by a ligase? | Proteomics with knockout or overexpression followed by ubiquitin enrichment. |
How to Study the ubiquitin ligase complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Protein-protein interactions | Identify subunits and substrates of a ligase complex. |
| Mass spectrometry | Protein identification and ubiquitination sites | Map substrate repertoire and ubiquitin chain linkages. |
| Cryo-EM | 3D structure of complexes | Determine assembly and conformational states. |
| In vivo ubiquitination assay | Substrate ubiquitination levels | Validate ligase-substrate relationship. |
| CRISPR knockout screen | Genes required for a phenotype | Discover regulators of ligase complex function. |
| RNA-seq | Transcriptional changes | Assess downstream effects of ligase loss or overexpression. |
| Western blot | Protein stability and expression | Monitor substrate degradation upon ligase manipulation. |
| Proximity labeling | Interacting proteins in living cells | Identify transient interactions in ligase complexes. |
Proteomics and ubiquitin enrichment
Mass spectrometry-based proteomics combined with ubiquitin remnant enrichment can identify substrates and ubiquitination sites regulated by a specific ligase complex. Comparing wild-type and knockout cells reveals candidate substrates.
Structural biology
Cryo-EM and X-ray crystallography provide high-resolution views of ligase complex assembly, as shown for the pentameric KCTD5/CUL3 complex. These studies reveal how subunits interact and how conformational changes regulate activity.
Cell-based ubiquitination assays
In vivo ubiquitination assays using tagged ubiquitin and immunoprecipitation can monitor substrate ubiquitination in response to ligase manipulation. This approach is useful for validating specific substrate-ligase relationships.
CRISPR screening
Genome-wide CRISPR knockout screens can identify genes that modulate ligase complex function or substrate degradation. Such screens are powerful for discovering new components or regulators.
How CRISPR Can Be Used to Study GO:0000151 ubiquitin ligase complex
Knockout
CRISPR knockout of a ligase subunit gene (e.g., CUL3, KEAP1) abolishes complex function and allows assessment of substrate accumulation and downstream phenotypes. Knockout cell lines are essential for validating substrate specificity and for proteomic studies.
Point Mutation
Point mutations can be introduced to disrupt catalytic activity (e.g., RING domain mutations) or to mimic disease-associated variants without affecting protein expression. Such models help distinguish catalytic vs. scaffolding functions.
Knock-in
Knock-in of tagged versions (e.g., GFP, HA, or BirA) at the endogenous locus enables imaging, immunoprecipitation, and proximity labeling of the ligase complex in its native context. Disease-relevant mutations can also be knocked in to study their effects on complex assembly.
Overexpression
Overexpression of a ligase or its substrate can amplify ubiquitination signals and reveal dose-dependent effects. This is particularly useful for studying substrate degradation and for screening small molecule modulators.
How EDITGENE Supports ubiquitin ligase complex Research
Researchers studying ubiquitin ligase complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, substrate recognition, or downstream phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for ubiquitin ligase complex research.
Frequently Asked Questions About ubiquitin ligase complex
What is GO:0000151?
GO:0000151 is the Gene Ontology term for ubiquitin ligase complex, a cellular component defined as a protein complex that includes a ubiquitin-protein ligase and enables ubiquitin protein ligase activity.
What is the function of the ubiquitin ligase complex?
It catalyzes the transfer of ubiquitin from an E2 enzyme to substrate proteins, thereby controlling their stability, localization, or interactions.
What genes are involved in ubiquitin ligase complexes?
Genes include CUL3, KEAP1, KCTD5, WWP2, MDM2, SKP2, FBXW7, VHL, RBX1, and many E2 conjugating enzymes like UBE2D1.
How is the ubiquitin ligase complex regulated?
It is regulated by neddylation of cullins, deubiquitinases, and post-translational modifications of subunits that affect assembly and activity.
What diseases are associated with ubiquitin ligase complex dysfunction?
Dysregulation is linked to cancer, cardiovascular disease, and protein quality control disorders.
What are examples of ubiquitin ligase complexes?
Cullin-RING ligases (CRLs) such as CUL3-based complexes and HECT-type ligases like WWP2 are well-studied examples.
How can I study ubiquitin ligase complex assembly?
Structural biology (cryo-EM), co-immunoprecipitation, and proximity labeling are commonly used to study assembly.
What CRISPR models are useful for studying ubiquitin ligase complexes?
Knockout, point mutation, knock-in, and overexpression models are all valuable for dissecting subunit function and substrate relationships.
Can ubiquitin ligase complexes be targeted therapeutically?
Yes, they are considered druggable, and small molecules or degraders targeting these complexes are under development.
What is the difference between RING and HECT ligases?
RING ligases transfer ubiquitin directly from E2 to substrate, while HECT ligases form a thioester intermediate with ubiquitin before transferring it to substrate.
Conclusion
The ubiquitin ligase complex (GO:0000151) is a central cellular component that governs protein ubiquitination and thereby influences nearly every aspect of cell biology. Its multi-subunit nature allows for exquisite substrate specificity and regulation, and its dysfunction is implicated in cancer, cardiovascular disease, and protein quality control disorders. Continued research using advanced CRISPR models and proteomic approaches will further illuminate its mechanisms and therapeutic potential.
References
- 1. Swatek KN et al.. 2016. Ubiquitin modifications.. Cell Res 26(4):399-422 PMID: 27012465
- 2. Liu F et al.. 2024. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.. Mol Cancer 23(1):148 PMID: 39048965
- 3. Mevissen TET et al.. 2017. Mechanisms of Deubiquitinase Specificity and Regulation.. Annu Rev Biochem 86:159-192 PMID: 28498721
- 4. Zhu F et al.. 2024. CRL3(Keap1) E3 ligase facilitates ubiquitin-mediated degradation of oncogenic SRX to suppress colorectal cancer progression.. Nat Commun 15(1):10536 PMID: 39627198
- 5. Nguyen DM et al.. 2024. Structure and dynamics of a pentameric KCTD5/CUL3/Gβγ E3 ubiquitin ligase complex.. Proc Natl Acad Sci U S A 121(17):e2315018121 PMID: 38625940
- 6. Zhang N et al.. 2020. Selective targeting of ubiquitination and degradation of PARP1 by E3 ubiquitin ligase WWP2 regulates isoproterenol-induced cardiac remodeling.. Cell Death Differ 27(9):2605-2619 PMID: 32139900
- 7. Carrillo Roas S et al.. 2025. Convergence of orphan quality control pathways at a ubiquitin chain-elongating ligase.. Mol Cell 85(4):815-828.e10 PMID: 39879985
- 8. Ebadi P et al.. 2025. E3 ubiquitin ligases in signaling, disease, and therapeutics.. Trends Biochem Sci 50(11):960-976 PMID: 40940201
